About the Event
Gain Therapeutics (NASDAQ: GANX) is transforming drug discovery with its AI and supercomputer-powered technology platform SEE-Tx.® SEE-Tx® accelerates the drug discovery process from more than 2 years to less than 3 months, unlocks new treatment approaches by enabling the identification of novel protein binding sites, and is currently being applied to develop GT-02287 a new drug for the treatment of Parkinson’s disease.
Gain is ready to move into a Phase 1 clinical trials to evaluate GT-02287 in healthy volunteers to assess safety and pharmacokinetics, with the goal of identifying an optimal dose level for Phase 1b and Phase 2 trials. In addition to GBA1-Parkinsons’s has therapeutic potential in multiple additional neurodegenerative diseases, including Gaucher disease, idiopathic Parkinson’s disease, Lewy body dementia, and Alzheimer’s, creating a total addressable market that exceeds $15B.
Join our webinar with Gain CEO, Matthias Adler, for an update on the company’s progress and details about their upcoming clinical trials.